Small molecule drug could hold promise for treatment of arthritis
A Phase III clinical trial led by Stanford University (CA, USA) has demonstrated that baricitinib may be an effective therapy for refractory rheumatoid arthritis.
Please sign in or register for FREE
Sign in to MedChemNet
Register to MedChemNet
MedChemNet is a communal space where industry and academic professionals can come together to discuss the latest research and developments, share thoughts and opinions, and build valuable international relationships.